This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Robert C. Schlant, MD

JAMA. 1990;264(6):738-739.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In this issue of THE JOURNAL, Naylor and Jaglal¹ report the results of their meta-analysis of patients with acute myocardial infarction who were enrolled in seven randomized control trials of thrombolytic therapy with either tissue plasminogen activator or streptokinase between March 1982 and November 1987. The authors did a meta-analysis of the number of procedures (cardiac catheterization, coronary angioplasty, or surgical coronary revascularization) performed within 6 weeks of myocardial infarction in the patients in each study treated either with or without thrombolytic therapy. Overall, in the seven trials there was a relative increase of 80% in the number of revascularization procedures (angioplasty or bypass surgery) performed on the patients treated with thrombolytic therapy; the relative increase in the number of procedures was higher in patients treated with tissue plasminogen activator than in patients treated with streptokinase. A similar increase in coronary revascularization procedures after thrombolytic therapy for myocardial infarction . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, Emory University School of Medicine, Atlanta, Ga.

Footnotes
Reprint requests to Department of Medicine (Cardiology), Emory University School of Medicine, 69 Butler St SE, Atlanta, GA 30303 (Dr Schlant).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?